Company Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.
The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Neil K. Warma |
Contact Details
Address: 1920 Yonge Street, Suite 200 Toronto, ON M4S 3E2 Canada | |
| Phone | 416 847 6898 |
| Website | promisneurosciences.com |
Stock Details
| Ticker Symbol | PMN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374339 |
| CUSIP Number | 74346M406 |
| ISIN Number | CA74346M4065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil K. Warma M.B.A. | Chief Executive Officer, President, Compliance Officer and Director |
| Eugene W. Williams | Co-Founder and Chairman |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Dennis Chen Ph.D. | Head of Manufacturing and Senior Consultant |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 424B5 | Filing |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 19, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 8, 2025 | 8-K | Current Report |